Senores Pharmaceuticals Ltd
₹ 1,120
-1.26%
02 Nov
- close price
About
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
Key Points
- Market Cap ₹ 5,158 Cr.
- Current Price ₹ 1,120
- High / Low ₹ 1,600 / 706
- Stock P/E 38.6
- Book Value ₹ 218
- Dividend Yield 0.00 %
- ROCE 15.1 %
- ROE 13.4 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 5.14 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 13.9% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 187 days.
- Working capital days have increased from 67.9 days to 132 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| 14 | 35 | 215 | 398 | 633 | 719 | |
| 12 | 23 | 173 | 309 | 464 | 509 | |
| Operating Profit | 2 | 13 | 42 | 90 | 168 | 209 |
| OPM % | 14% | 36% | 19% | 23% | 27% | 29% |
| 0 | 4 | 3 | 19 | 47 | 37 | |
| Interest | 1 | 2 | 9 | 22 | 25 | 30 |
| Depreciation | 1 | 2 | 10 | 17 | 31 | 37 |
| Profit before tax | 1 | 12 | 25 | 71 | 159 | 179 |
| Tax % | 13% | 32% | -31% | 17% | 24% | |
| 1 | 8 | 33 | 58 | 122 | 137 | |
| EPS in Rs | 1.01 | 8.59 | 10.31 | 12.72 | 25.05 | 28.97 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 162% |
| TTM: | 39% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 139% |
| TTM: | 53% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 45% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 14% |
| Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 31 | 46 | 46 | 46 |
| Reserves | 28 | 36 | 174 | 740 | 888 | 957 |
| 15 | 63 | 258 | 315 | 342 | 417 | |
| 8 | 23 | 160 | 126 | 328 | 261 | |
| Total Liabilities | 59 | 131 | 622 | 1,227 | 1,604 | 1,681 |
| 7 | 27 | 235 | 301 | 755 | 851 | |
| CWIP | 8 | 34 | 97 | 172 | 17 | 31 |
| Investments | 15 | 16 | 0 | 0 | 4 | 6 |
| 29 | 53 | 289 | 754 | 827 | 792 | |
| Total Assets | 59 | 131 | 622 | 1,227 | 1,604 | 1,681 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -10 | -1 | -26 | -46 | 62 | |
| -24 | -48 | -54 | -429 | -121 | |
| 36 | 46 | 87 | 573 | -1 | |
| Net Cash Flow | 2 | -3 | 8 | 98 | -60 |
| Free Cash Flow | -21 | -48 | -78 | -203 | -203 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -526% | 3% | -56% | -41% | 45% |
Ratios
Consolidated / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 506 | 228 | 191 | 114 | 187 |
| Inventory Days | 135 | 89 | 184 | 232 | 130 |
| Days Payable | 324 | 388 | 556 | 275 | 340 |
| Cash Conversion Cycle | 317 | -71 | -182 | 70 | -24 |
| Working Capital Days | 359 | -7 | -16 | 88 | 132 |
| ROCE % | 18% | 12% | 11% | 15% |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Emerging Markets Approved Products (Registered) products |
|
||
| Approved ANDA Products (Strengths) - Regulated Markets products |
|||
| Branded Generics Field Force (MRs) - India employees |
|||
| CDMO/CMO Commercial Products - Regulated Markets products |
|||
| Commercialized ANDA Products (Strengths) - Regulated Markets products |
|||
| Emerging Markets Pipeline Products (Applications Filed) products |
|||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Senores Pharmaceuticals Limited has informed regarding Newspaper publication extracts of unaudited financial results for the quarter and half year ended September 30, 2026
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of Q2 and H1FY27 earnings conference call shared on October 29, 2026.
-
Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Raised Through Preferential Issue Of Convertible Equity Warrants, For The Quarter Ended On September 30, 2026
- Senores reported no deviation in use of ₹95.00 crore warrant proceeds for quarter ended September 30, 2026.
-
Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On September 30, 2026
- Senores reported no deviation in ₹500 crore IPO use; ₹418.83 crore utilized as of Sept 30, 2026.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- CARE monitoring report for quarter ended September 30, 2026 shows nil deviation and revised IPO utilization.
Concalls
-
Oct 2026PPT REC
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Jan 2026Transcript PPT REC
-
Dec 2025PPT
-
Nov 2025Transcript PPT REC
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
May 2025PPT
-
Jan 2025Transcript PPT REC
Business Overview:[1]
SPL is a global research-driven pharmaceutical company that develops and manufactures
pharmaceutical products for the Regulated Markets of the US, Canada, and the United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. The company develops and manufactures specialty, underpenetrated, and complex pharmaceutical products. It also manufactures critical care injectables and APIs.